A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain

Trial Profile

A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2013

At a glance

  • Drugs Hib-DTaP-hepatitis B-poliovirus vaccine; Hib-DTaP-poliovirus vaccine; Meningococcal vaccine group C conjugate; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal infections; Meningococcal meningitis; Otitis media; Pertussis; Pneumococcal infections; Pneumonia; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors Wyeth
  • Most Recent Events

    • 22 Jun 2011 Results published in Vaccine.
    • 29 Oct 2009 Results were presented at IDSA 2009.
    • 08 Aug 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top